Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review
Yazan Migdady, Asiri Ediriwickrema, Ryan P. Jackson, Wendy Kadi, Ridhi Gupta, Francisco Socola, Sally Arai, Beth A. Martin
Abstract
Key Points A source of treatment refractoriness in immune cytopenias appears to be residual CD138/38-positive lymphocyte populations. A short course of daratumumab is a novel treatment of refractory thrombocytopenia after failure of standard treatment options.
Topics & Concepts
DaratumumabMedicineRefractory (planetary science)Minimal residual diseaseImmune thrombocytopeniaOncologyInternal medicineIntensive care medicineImmunologyAntibodyMonoclonal antibodyBone marrowBiologyAstrobiologyPlatelet Disorders and TreatmentsImmunodeficiency and Autoimmune DisordersBlood disorders and treatments